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ABSTRACT
A systematic literature search revealed 35 clinical studies and one meta-analysis comprising 43,759
women, of which 13,096 were treated with isopropanolic Cimicifuga racemosa extract (iCR). Compared
to placebo, iCR was significantly superior for treating neurovegetative and psychological menopausal
symptoms, with a standardized mean difference of 0.694 in favor of iCR (p< 0.0001). Effect sizes
were larger when higher dosages of iCR as monotherapy or in combination with St. John’s wort
(Hypericum perforatum [HP]) were given (1.020 and 0.999, respectively), suggesting a dose-depend-
ency. For psychological symptoms, the iCRþHP combination was superior to iCR monotherapy.
Efficacy of iCR was comparable to low-dose transdermal estradiol or tibolone. Yet, due to its better tol-
erability, iCR had a significantly better benefit–risk profile than tibolone. Treatment with iCR/iCRþHP
was well tolerated with few minor adverse events, with a frequency comparable to placebo. The clin-
ical data did not reveal any evidence of hepatotoxicity. Hormone levels remained unchanged and
estrogen-sensitive tissues (e.g. breast, endometrium) were unaffected by iCR treatment. As benefits
clearly outweigh risks, iCR/iCRþHP should be recommended as an evidence-based treatment option
for natural climacteric symptoms. With its good safety profile in general and at estrogen-sensitive
organs, iCR as a non-hormonal herbal therapy can also be used in patients with hormone-dependent
diseases who suffer from iatrogenic climacteric symptoms.
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Up to 80% of climacteric women, especially those suffering
from hot flushes, use complementary and alternative medi-
cine, mainly without informing their health-care providers1–5.
This highlights not only patients’ wishes but also a need for
evidence-based information on the efficacy and safety of
these treatments.
One of the most popular herbal remedies is Cimicifuga
racemosa (CR) syn. Actaea racemosa (black cohosh). CR has
been used by Native Americans and eclectic physicians as a
gynecological remedy and for rheumatism and other condi-
tions. The earliest literature references date back to the
seventeenth century6. The first allopathic herbal medicinal
product (HMP) containing CR rootstock extract was intro-
duced in Germany in 1956 and has been extensively studied
since7. In Germany, where HMPs are authorized medicines
under strict regulatory control requiring state-of-the-art proof
of efficacy, safety, and pharmaceutical quality, gynecologists
rate CR treatment as well-known and effective for climacteric
symptoms8. In many other countries, CR products are mar-
keted as food supplements (FS). FS are not as rigorously con-
trolled as HMPs and run the risk of adulteration and
contamination. Frequently, FS claiming to consist of authen-
tic North American CR have contained completely different
Asian Cimicifuga species9. While FS often have little or no sci-
entific evidence behind them, they are regarded as comple-
mentary and alternative medicine. On the other hand, (CR)
HMPs are evidence-based rational phytopharmaceuticals and
should be treated as such10.
In 2011, and again in 2018, the European Medicines
Agency issued an official monograph with a positive
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benefit–risk ratio for CR HMPs for the treatment of climac-
teric symptoms11,12. A Cochrane review doubted CR’s super-
iority versus placebo for menopausal symptoms13 but was
internationally criticized soon after. Apart from a failure to
identify all appropriate randomized controlled trials (RCTs)
and an incorrect exclusion of positive results, the review’s
main shortcoming was a missing differentiation between the
extracts used14. The new meta-analysis showed CR to be sig-
nificantly superior to placebo for menopausal symptoms14.
Unlike synthetic drugs, the active ingredient of phytophar-
maceuticals is not a single substance but the whole plant
extract. Herbal extracts contain a multitude of different con-
stituents and – even if derived from the same plant – their
composition varies depending on many factors (e.g. cultiva-
tion, harvesting conditions, extraction process, extractant,
and standardization) that may lead to different effects and
efficacies15. Therefore, study results gained with a specific
extract cannot be transferred one-to-one to different extracts
of this herb. For phytopharmaceuticals there are no genuine
generics as with synthetic drugs. Consequently, when analyz-
ing scientific data, it is crucial to differentiate between HMPs
and non-HMPs/FS and between different extracts. The first
differentiated evaluation of extract-specific evidence on CR’s
efficacy and safety was performed by Beer and Neff in
201316. Their analysis of publications from 2000 to 2012
came to the conclusion that only HMPs, but not FS/non-
HMPs, of CR demonstrated evidence for their efficacy. Best
evidence was provided by the isopropanolic CR extract (iCR);
the only extract tested in several thousand women and the
only extract that provided confirmatory Level 1 evidence and
Grade of Recommendation A16. These results were confirmed
by an additional analysis of newer studies published from
2012 to 201417.
This review’s purpose is to give a current update and
overview of all placebo-controlled clinical data (irrespective
of publication date) and additional data from clinical studies
with iCR during a broader time span ranging from the estab-
lishment of the EU Guideline on Good Clinical Practice E6 in
1997 until January 2020. Furthermore, for the first time, all
placebo-controlled data gained with iCR are pooled in a
meta-analysis. Efficacy and safety results are analyzed in
detail and discussed in order to enable health-care providers
to advise patients who refuse or have contraindications to
hormone therapy for climacteric symptoms.
Methods
MEDLINE, EMBASE, EMBASE Alert, BIOSIS, and PubMed were
searched for clinical studies with iCR (irrespective of design)
and meta-analyses thereof, published from 1997 to January
2020, as a basis for our review. Furthermore, all available
randomized placebo-controlled data, irrespective of publica-
tion date, were collected as a basis for our meta-analysis.
The database search was complemented by a manual search
in the authors’ library and an additional search in
ClinicalTrials.gov and the EU Clinical Trials Register.
Inclusion criteria were medical use of iCR, efficacy for neu-
rovegetative and psychological climacteric symptoms,
additional clinical benefits, occurrence and frequency of
adverse events, and influence on liver, hormones, and estro-
gen-sensitive organs. No restrictions regarding patients’ ages,
menopausal status, and treatment duration were made.
Patient-relevant endpoints were reduction of neurovegetative
and psychological climacteric symptoms (e.g. scales for cli-
macteric symptoms, symptom frequency and intensity, and
objective symptom measurement), additional clinical bene-
fits, and frequency and severity of adverse events, including
influence on estrogen-sensitive organs or laboratory
parameters.
Studies were sorted according to their quality and the
RCTs regarding their control group (placebo, active compara-
tor). The placebo-controlled RCTs were pooled in the meta-
analysis and independently assessed for risk of bias with the
revised Cochrane RoB 2 tool (2019) by three authors (M.G.,
H.H.H.-v.Z., and S.P.). Disagreements were discussed until a
consensus was reached. The meta-analysis was performed
using SAS version 9.4 under the fixed-effect size model. For
studies that did not directly report the standardized group
difference and the corresponding confidence interval, these
parameters were deduced either from the published means,
standard deviations, and sample size N or from the published
means, sample size N, and p-values.
Results
The search revealed one meta-analysis18 and 35 clinical stud-
ies19–53, including 16 RCTs19–31,50,52,53, that met the inclusion
criteria. Altogether, 43,759 patients were included in the
studies; 13,096 of the patients were treated with iCR. A
detailed overview of populations, interventions, and results
for each study is presented in Table S1.
Efficacy for natural menopausal symptoms
Placebo-controlled, double-blind RCTs
The first RCT demonstrated that iCR was superior to placebo
in improving the Kupperman Menopause Index (KMI) and
the Hamilton Anxiety Rating Scale19 scores for all assessment
points (4, 8, and 12weeks; p< 0.001). In the iCR group, the
average symptom intensity decreased from ‘moderate’ at
baseline to ‘mild’ at study termination, showing a good
therapeutic result. In the placebo group, it decreased but still
remained ‘moderate’.
Significantly greater improvements in the total
Menopause Rating Scale (MRS) scores were found in patients
taking iCR for 3months compared to placebo (p< 0.001)22.
Efficacy was best for vasomotor symptoms (hot flushes,
sweating, and sleep disorders). With 0.03–0.05 MRS units, the
effect size was similar to that of 0.6mg conjugated estrogens
in a previous study and clinically relevant. The therapeutic
benefit was highest in patients who were treated in the early
climacteric phase.
In iCR-treated patients, significantly higher reductions in
climacteric symptom severity (total KMI and hot flush scores)
were seen after 4weeks (p< 0.05 for KMI, p¼ 0.041 for hot
flushes) and 12weeks (p< 0.001 for KMI, p¼ 0.021 for hot
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flushes) compared to placebo26. iCR noticeably decreased
both scores from baseline to study termination (KMI,
26.46 ± 10.46 to 6.37 ± 4.16; hot flushes, 7.52 ± 2.37
to 1.52 ± 1.97).
Polysomnography, conducted to objectively measure
sleep disturbances in a 6-month trial, showed that patients
using iCR had significantly increased sleep efficiency
(p¼ 0.01) and decreased wake after sleep onset duration
(p< 0.01) compared to placebo. Vasomotor and physical
domains of the Menopause-specific Quality of Life question-
naire also improved versus placebo31.
The fixed combination of high-dose iCR plus low-dose St.
John’s wort (Hypericum perforatum) (iCRþHP) was significantly
superior to placebo in improving MRS (50%) and Hamilton
Depression Rating Scale scores (41.8%) (p< 0.001)24.
Active-controlled RCTs
A 3-month study compared the efficacy of iCR to low-dose
transdermal estradiol for climacteric symptoms23. Both treat-
ments significantly reduced the number of hot flushes/day
and vasomotor symptoms as well as anxiety and depression
(p< 0.001 for all). Both treatments showed comparable effi-
cacy without significant differences.
Chinese women with climacteric symptoms received
either iCR or tibolone for 3months in a double-blind, dou-
ble-dummy trial25. A noticeable and clinically relevant reduc-
tion of similar size for the KMI scores was seen in both
groups, significantly demonstrating non-inferiority of iCR
(p¼ 0.002). Yet, due to its better tolerability, iCR was superior
to tibolone in the benefit–risk ratio (p¼ 0.01).
In two further RCTs, significant KMI score reductions of
perimenopausal symptoms were shown under iCR after
3months; they were comparable to those under tibo-
lone52,53. Additionally, vaginal atrophy symptoms were sig-
nificantly ameliorated in both groups, without significant
group differences53.
Treatment with a standard dose (SD) or high dose (HD) of
iCR for 6months significantly decreased menopausal symp-
toms (KMI score reduced by 75%). The responder rate was
already 70% after 3months. These effects were maintained
after 6months21. For the complete study population, no dif-
ferences between SD and HD could be observed. However,
patients who were in the early climacteric phase benefited
significantly more from HD compared to SD and also exhib-
ited a response rate above 90% when using HD21,54.
Women with perimenopausal depression were treated with
either paroxetine or paroxetine plus iCR for 2months28. The
iCR group showed significantly better improvement in the
Hamilton Depression Rating Scale (p< 0.05) and KMI (p< 0.01)
scores compared to patients taking only paroxetine.
A 12-week iCR treatment was compared to placebo treat-
ment in patients with postmenopausal atrophic vaginitis27.
While atrophic vaginitis symptoms were significantly reduced
in the iCR group (p< 0.05), there were no significant influen-
ces on vaginal pH or the maturation degree of vaginal epi-
thelial cells.
Open, controlled studies
In a prospective, controlled observational study, 6,141
patients were treated for 6–12months (n¼ 736) with iCR or
iCRþHP according to the physicians’ choices32. Both treat-
ments led to significant reductions of the MRS total score
and the MRS subscore ‘psyche’. The iCRþHP combination
was superior to the monotherapy in ameliorating psycho-
logical climacteric symptoms (p< 0.001).
Compared to untreated control, iCR-treated women
showed significant decreases in the urinary concentration of
N-telopeptides (bone resorption marker) and increases in
serum alkaline phosphatase (bone formation marker)
after 3months33.
Open, uncontrolled studies
Two studies using a 3-month iCR therapy found significant
reductions in the KMI scores. The most pronounced improve-
ments were seen for hot flushes and sweating42,43. Sleeping
difficulties and anxiety were also greatly reduced43.
Postmenopausal women with increased body weight taking
iCR for 3months experienced a significant increase in their
quality of life (Cervantes Health-Related Quality-of-Life Scale),
especially in the ‘menopause/health’ and ‘psyche’ domains47.
Another 3-month study found that more than 70% of
women using iCR had fewer hot flushes, less sweating, and
fewer psychological complaints (irritability, depressive moods,
and insomnia)45. Patients taking HD iCR for 98 days exhibited
reductions in 10 typical neurovegetative climacteric symp-
toms. Efficacy was rated as good or very good in 80% of the
cases40. The combination of iCRþHP ameliorated not only
psychological but also neurovegetative symptoms of meno-
pause significantly after 12weeks of therapy. Efficacy was
judged as good or very good in 81% of the cases39.
Efficacy for iatrogenic menopausal symptoms
Placebo-controlled, double-blind RCTs
Breast cancer patients, most treated with tamoxifen, received
either iCR or placebo for 2months. While both groups had a
comparable decline in the number and intensity of hot
flushes, the iCR-treated women reported significantly less
sweating than the placebo group (p¼ 0.04)20.
Active-controlled RCTs
Endometriosis patients were treated with postoperative
goserelin therapy, causing estrogen-deficiency symptoms30.
Four weeks after the first goserelin injection, they received
add-back therapy with tibolone or iCR for 12weeks. Both
treatments significantly reduced KMI and hot flushes/sweat-
ing scores to a comparable extent without significant group
differences. The iCR group had significantly fewer adverse
events and less vaginal bleeding/spotting or breast pain.
Open, controlled studies
Women with early breast cancer were treated with luteiniz-
ing hormone-releasing hormone analogue after surgery,
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mostly combined with endocrine therapy. They randomly
received iCR or no treatment for 3months. The iCR group
had significantly lower KMI scores compared to control50.
Patients with stage 1 endometrial cancer suffering from
menopausal symptoms after surgery were treated with iCR
for 24weeks or remained untreated as control35. All patients
were followed for 12months. Therapy with iCR resulted in a
significant decrease of the KMI score and a significant
increase in bone mineral density (both p< 0.05).
Open, uncontrolled studies
A pilot trial in women (breast cancer, high risk, or refused
hormone therapy) with significant hot flushes, partly caused
by tamoxifen or raloxifene, found a reduction of hot flush
frequency (50%), severity (22%), and sweating (80%)
after 4weeks of iCR intake41. Additionally, patients reported
less sleeping problems and less fatigue.
Patients after surgery for gynecological cancers (endomet-
rial, ovarian, cervix, borderline ovarian, and breast cancers)
experienced a significant reduction of KMI scores, hot
flushes, sweating, and depressive moods after 3months of
treatment with iCR (p< 0.05)48.
Women after breast cancer surgery suffering from tamoxi-
fen-induced climacteric symptoms were treated with iCR for
6months. The dosage was adapted to symptom intensity49.
The iCR treatment led to significant reductions in the total
MRS II score (p< 0.001). Hot flushes, sweating, sleep prob-
lems, and anxiety improved most.
Meta-analysis of the placebo-controlled RCTs
All placebo-controlled RCTs examining efficacy for neuro-
vegetative and psychological climacteric symptoms were
included in the meta-analysis19,20,22,24,26,31. Most of the RCTs
had a low risk of bias19,22,24. Two RCTs raised some con-
cerns20,31 and one RCT was rated as high risk according to
RoB 2 criteria26 (Figure 1; extensive assessment presented in
Table S2). However, the latter suffered explicitly from low-
quality reporting, which may not necessarily imply an actual
risk of bias. Detailed characteristics of these RCTs are pre-
sented in Table 1. Figure 2 shows a forest plot of these RCTs,
revealing an overall standardized mean difference of 0.694
in favor of iCR (p< 0.0001). By subgroups, the standardized
mean difference in favor of iCR was 0.568 for natural
menopausal symptoms, 0.187 for iatrogenic symptoms, and
0.999 in favor of iCRþHP for natural climacteric symptoms.
For studies with higher iCR dosages as monotherapy or in
combination with HP19,24, the standardized mean difference
in favor of iCR was 1.020 and 0.999, respectively.
Safety in general and at the liver
Treatment with iCR was generally well tolerated with few
minor adverse events19,21–23,25,30,32,33,39,41,43–45,52 or even no
adverse events27,31,35. Compared to placebo, the frequency
of adverse events under iCR or iCRþHP was not significantly
different22,24. HD iCR demonstrated the same good tolerabil-
ity as SD iCR21. In breast cancer patients treated with tamoxi-
fen, typical tamoxifen-associated adverse effects occured20,49.
Compared to tibolone, iCR treatment had significantly fewer
adverse effects, especially for vaginal bleeding or spot-
ting25,30,52,53. No significant influences of iCR on body
weight/body mass index22,25,35, heart rate22, blood pres-
sure22,28,35, or electrocardiogram28 were seen. Routine
hematology21,24,25,28,48, routine biochemistry21,24,25,33,48,
including kidney function tests21,24,25,28,30,31,35,48,52,53, and
urinalysis25,28,48 remained unaffected by iCR. Regarding lipid
metabolism, total cholesterol and triglycerides were not
affected23,26,30,33,35,44,48,52,53. However, several investigators
reported significant increases of high-density lipoprotein
cholesterol and decreases of low-density lipoprotein
cholesterol23,26,48,52.
A meta-analysis of five double-blind RCTs including 1117
patients showed that SD or HD iCR treatment for 3–6months
did not significantly influence liver function tests and did not
reveal any evidence for hepatotoxicity18. Ten further
studies23,26,28,30,31,35,48,52,53,55, seven of which were RCTs,
including 741 patients also did not find any significant
changes in liver function parameters.
Safety at estrogen-sensitive organs
Taking SD iCR for 3–6months did not lead to significant
changes in gonadotropin or estradiol levels in otherwise
healthy women (n¼ 481)21,23,26,27,31,33,40,46,52,53 or in women
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Figure 1. Risk of bias assessment of the placebo-controlled randomized controlled trials (RCTs).






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































gynecological tumors, and endometriosis)
(n¼ 193)20,30,35,48,50. HD iCR also did not affect follicle stimu-
lating hormone, luteinizing hormone, or estradiol21,40.
Furthermore, prolactin, sex hormone binding globulin, and
testosterone remained unchanged21,23,33,40,44.
Ultrasound scans showed that endometrial thickness was
not influenced by 3–6-month iCR treatment
(n¼ 516)23,25–27,31,40,44,50,52,53. Also, in patients with uterine
pathologies like endometriosis or endometrial carcinoma,
pelvic ultrasound was unremarkable (n¼ 86)30,35. iCR therapy
in goserelin-treated endometriosis patients resulted in signifi-
cantly less vaginal bleeding/spotting than add-back therapy
with tibolone30. Using iCR for 3months led to a significant
reduction of myoma volume compared to baseline (30%)
and compared to tibolone, which had no significant effects
(þ4.7%)29. Patients with endometrial cancer had no increase
of tumor marker CA 125 or recurrences during 6-month iCR
treatment and 12-month follow-up35. No significant changes
of vaginal cytology/maturation index or pH could be
detected after 3–6-month treatment with SD or HD
iCR21,26,27,40.
Breast ultrasonography did not reveal any changes after
6-month iCR treatment in healthy women and in women
after therapy for estrogen-dependent tumors (n¼ 54)31,35.
Furthermore, no signs of increased mammographic breast
density (visual assessment) or breast cell proliferation (fine-
needle aspiration biopsy) were found after 6-month iCR
treatment44. These results were confirmed by digitized
assessment of the mammograms34. Patients with ductal car-
cinoma in situ, using iCR for 2–5weeks pre surgery, experi-
enced no significant changes in proliferation marker Ki67, yet
a downward trend was seen51. Two case–control studies
demonstrated that iCR use was associated with a reduced
risk for breast cancer37,38. The larger study found that risk
reduction was independent of lifestyle factors, tumor hist-
ology, and receptor status, but improved with longer
treatment duration. A pharmacoepidemiological cohort study
in breast cancer survivors demonstrated that women taking
iCR for climacteric symptoms compared to women not using
iCR had a significantly lower risk for recurrence with a 4.5-
year longer recurrence-free survival on average36.
Discussion
All studies with iCR consistently demonstrated its efficacy for
natural climacteric symptoms, exhibiting significant superior-
ity versus placebo and an efficacy comparable to low-dose
transdermal estradiol or
tibolone19,21–26,28,31,32,39,40,42,43,45,47,52,53. Yet, due to its better
tolerability, iCR had a better benefit–risk profile than tibo-
lone. These results confirm the NICE guideline meta-analyses.
There, CR was significantly superior to placebo in reducing
vasomotor symptom frequency, revealing a good effect size,
whereas tibolone was associated with high treatment discon-
tinuation56. It is noteworthy that among all non-hormonal
treatments, CR exhibited the largest effect size and had the
highest probability of being the best treatment56. However,
the guideline calls for caution concerning the great variety
of CR products. This makes sense because inconclusive data
on CR’s efficacy result from products that do not meet the
strict criteria for HMPs16,17. With a standardized mean differ-
ence of 0.568 in favor of iCR versus placebo for natural
menopausal symptoms in our meta-analysis, iCR, as an
authorized HMP, offers an evidence-based, recommendable,
non-hormonal treatment. The inclusion of one publication
with a potential for high risk of bias26 in our meta-analysis
could be worth discussing. However, as its effect size does
not deviate from the overall treatment effect, its inclusion or
exclusion has no impact on the result of this meta-analysis.
Most of the included studies had a low risk of bias19,22,24.
Our meta-analysis shows higher effect sizes when higher
doses of iCR (without or with HP)19,24 were used (standard
Figure 2. Forest plot of isopropanolic Cimicifuga racemosa extract (iCR) versus placebo in neurovegetative and psychological menopausal symptoms.
CI, confidence interval; Fixed, summary of the respective group of studies under the fixed-effect size model; HP, Hypericum perforatum (St. John’s wort); ms, menopausal symptoms; n,
number of patients; Std diff, standardized mean difference; SE, standard error of the standardized difference.
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mean difference of 1.020 and 0.999, respectively), sug-
gesting a dose-dependency. Women in their early climacteric
phase may benefit from an increase from 40mg up to
120mg drug/day54. Furthermore, iCRþHP was superior to iCR
in ameliorating psychological climacteric symptoms32. With
its higher iCR dose and synergistic effects with HP, the com-
bination offers a valuable treatment option not only in terms
of its greater effect size shown in our meta-analysis but also
because psychological symptoms like depressive moods
often occur during perimenopause57,58.
Efficacy data concerning iatrogenic climacteric symptoms
are varied, with the findings being predominantly positive.
Climacteric symptoms after endometrial cancer surgery were
significantly reduced by iCR over 24weeks compared to
untreated control35. These positive effects are in line with
results of another 24-week, hormone therapy-controlled
study with iCR in hysterectomized patients59. For goserelin-
induced symptoms in endometriosis patients, 12weeks of
iCR treatment was as effective as add-back therapy with tibo-
lone, yet more tolerable30. These results were recently con-
firmed by a study in gonadotropin-releasing hormone
analogue-treated breast cancer patients. There, iCR treatment
significantly lowered KMI scores after 12weeks compared to
control50. In tamoxifen-treated breast cancer patients, hot
flush reductions over 8weeks under iCR were not signifi-
cantly different from placebo, but the sample size was too
small to prove superiority; however, iCR-treated patients still
benefited from significantly less sweating20. This study was
too short to expect significant efficacy results. The authors
assumed that ‘it is possible that when used for a longer
period of time, black cohosh may show greater efficacy’.
Excluding this study with a shorter treatment duration than
the US Food and Drugs Administration and the European
Medicines Agency require would have increased the homo-
geneity of our meta-analysis results. Significant reductions of
iatrogenic hot flushes, sweating, and psychological symp-
toms were shown in longer open studies (12–24weeks)48,49.
There, tamoxifen-treated breast cancer patients were also
allowed to double the standard iCR dose49. This could
enhance treatment effects, as practical experience showed
that patients with tamoxifen-induced symptoms often need
higher CR doses than natural menopausal women60. Thus,
HD iCR or iCRþHP can be used to treat climacteric symptoms
induced by endocrine therapy. These patients cannot take
hormones and without additional therapy may discontinue
the anti-hormonal treatment due to its severe side
effects60–62.
Treatment with SD/HD iCR or iCRþHP was well tolerated
with only rare minor adverse effects, no significant differen-
ces from placebo, and significantly better tolerability com-
pared to tibolone19,21–25,27,28,30,31,33,35,39–45,48,49,52,53. This
favorable safety profile of iCR is congruent with data ana-
lyzed for CR extracts in general13,16,17,63. None of the iCR
studies showed liver-specific side effects. Additionally, a
meta-analysis of five RCTs and 10 further studies, 1858
patients in total, showed no influence of iCR on liver
function18,23,26,28,30,31,35,48,52,53,55. Single cases of hepatotox-
icity had been reported during the use of CR products.
These included FS that do not meet the strict quality
criteria of HMPs and are often adulterated with different
Asian Cimicifuga species9. Case report assessment with a
liver-specific diagnostic algorithm did not reveal a causal
relationship64–67.
In the past it was believed that CR’s efficacy may be
based on estrogen-like effects due to its reputed constituent
formononetin. However, this isoflavone was never detected
in CR extracts used for the manufacture of iCR68,69. Activity
on estrogen receptors was not shown for iCR70. Instead,
binding and modulation of central nervous system key
receptors for thermoregulation, mood, and sleep (e.g. sero-
tonin, dopamine, c-aminobutyric acid, m-opioid) and favor-
able changes in brain metabolism and activity were
observed46,71–75. These mechanisms of action explain not
only the efficacy for climacteric symptoms but also the fact
that iCR did not influence hormones, breast tissue density or
proliferation, endometrial thickness, or vaginal
cytology20,21,23,25–27,30,31,33–35,40,44,48,50,52,53. The amelioration
of vaginal atrophy symptoms observed by some researchers
can possibly be explained by anti-inflammatory and anti-oxi-
dative effects of CR. The reduction of psychological meno-
pausal symptoms by iCR may also play an important role in
this regard, as psychological stress impairs vaginal health
and sexual function. Against this background and in line
with the official monographs, the benefit–risk ratio of iCR/
iCRþHP is clearly positive. The resulting recommendation of
iCR for patients with climacteric symptoms is fortified by
results of the NICE guideline health economic model. Out of
all treatments in hysterectomized women and in women
with a uterus, CR had the second highest and the highest
probability, respectively, of being the most cost-effective
treatment76.
Furthermore, initial data suggest additional benefits. The
longer recurrence-free survival in breast cancer patients tak-
ing iCR36 and an association of iCR therapy with a decreased
risk of developing breast cancer37,38 are substantiated by
experimental data. iCR dose-dependently inhibited the prolif-
eration of estrogen-dependent and estrogen-independent
breast cancer cells due to caspase activation and induction
of apoptosis; it reduced invasiveness and enhanced the
effects of tamoxifen77–81. CR downregulated the expression
of estrogen receptor-a, progesterone receptor, and BRCA1 in
hormone-dependent breast cancer cells and decreased their
proliferation82. In breast cancer animal models, application of
iCR indicated a trend toward or actually led to reduced
tumor growth – the latter accompanied with prolonged life
span83,84. Combination of tamoxifen with iCR increased the
incidence of tumor-free animals and reduced the individual
tumor burden85.
Further mechanisms of action of CR and its constituents
may contribute to iCR’s beneficial effects (not only) in breast
cancer patients. Actein, a CR triterpene glycoside, had
growth inhibitory effects on human breast cancer cells asso-
ciated with activation of stress response pathways86. Actein
had anti-angiogenic effects in vitro and decreased breast
tumor size and metastasis in the mouse 4T1 breast tumor
model87. Recently, actein was found to suppress human
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bladder cancer cell proliferation and induce autophagy and
apoptosis via activation of reactive oxygen species/c-Jun N-
terminal kinase and inhibition of the AKT/mammalian target
of rapamycin (mTOR) pathway. The latter is activated in
breast and other cancers, leading to tumor cell growth, pro-
liferation, metastasis, and angiogenesis, and is implicated in
endocrine resistance88–90. Additionally, CR and some of its
components activated 50 adenosine monophosphate-acti-
vated protein kinase (AMPK) to the same extent as metfor-
min91. AMPK activation and mTOR inhibition suppressed the
proliferation and angiogenesis of leiomyoma cells, and mTOR
inhibition decreased the tumor incidence, multiplicity, and
size in the Eker rat model for myoma92–94. AMPK activation
and mTOR inhibition may explain the observed shrinking of
myoma under iCR treatment.
Clinical findings suggesting osteoprotective effects of iCR
are supported by experimental data: iCR dose-dependently
increased osteoprotegerin production (and thereby the
osteoprotegerin–RANK ligand ratio) in human osteoblasts,
which inhibits osteoclast differentiation and activity and may
impede bone resorption95,96. The osteoblast differentiation
markers osteocalcin and alkaline phosphatase activity were
increased95,96. In the ovariectomized rat model for osteopor-
osis, iCR augmented bone density and quality97, protected
against bone loss, and increased trabecular bone structure
and resistance98. 25-acetylcimigenol xylopyranoside (ACCX), a
CR triterpene glycoside, inhibited osteoclastogenesis by abro-
gation of the nuclear factor-jB and ERK pathways induced
by RANK ligand or tumor necrosis factor-a99.
Oxidative stress and inflammatory processes play a signifi-
cant role not only in menopausal vasomotor symptoms but
also in the development and progression of osteoporosis,
(breast) cancer, myoma, and further age-related conditions
(e.g. cardiovascular disease and cognitive decline)100–103. As
iCR exhibited anti-oxidative and mitochondria-protective
effects104 and recent evidence demonstrated strong anti-
inflammatory effects for CR105, these effects may contribute
to iCR’s efficacy for vasomotor symptom and to possible add-
itional benefits for patients with breast cancer, myoma, or
risk for osteoporosis. With numerous mechanisms of action
that may explain such benefits, iCR offers an interesting field
for future research, especially for diseases with underlying
inflammatory, AMPK, or mTOR dysregulation.
Conclusion and practical consequences
In summary, the clinical data and our meta-analysis consist-
ently demonstrate that iCR/iCRþHP is an effective and safe,
evidence-based treatment option for natural neurovegetative
and psychological climacteric symptoms, meeting increasing
patients’ demands for non-hormonal, herbal therapies. As
benefits clearly outweigh risks, iCR/iCRþHP should be recom-
mended to these women. With its good safety profile in gen-
eral and at estrogen-sensitive organs, iCR can also be used in
patients with hormone-dependent tumors suffering from iat-
rogenic menopausal symptoms. However, this should not
take place in self-medication but under medical supervision.
Breast-cancer patients are not appropriate candidates for
non-supervised self-medication, and it seems reasonable that
HD iCR or alternatively iCRþHP are more effective in patients
with medication-induced symptoms. Breast cancer patients
taking iCR may possibly benefit from prolonged recurrence-
free survival, which should be confirmed by further clin-
ical trials.
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